ESSA Pharma

ESSA Pharma: Developing novel therapies for the treatment of prostate cancer targeting the N-terminal domain of the androgen receptor. ESSA’s lead candidate, EPI-7386, is a first-in-class, highly-selective, oral, small molecule N-terminal domain inhibitor currently being evaluated in a Ph 1 trial as a monotherapy in patients with castration-resistant prostate cancer (CRPC) and in a Phase 1/2 trial in combination with Astellas' and Pfizer’s antiandrogen enzalutamide in patients with metastatic CRPC.
Based in...
US - Pacific
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Men's Health, Oncology
Public, USA
Market Cap
100MM - 500MM
400 Oyster Point Blvd.
South San Francisco, CA 94080
United States

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • David Parkinson, President/CEO

Top 10 Holders of ESSA Pharma Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
BVF, Inc. 19.84 8,748,629 27.03 13F 6/30/23
Bellevue Asset Management AG 17.91 7,898,583 24.41 13F 6/30/23
PFM Health Sciences LP 9.54 4,204,953 12.99 13F 6/30/23
Soleus Capital Management LP 9.53 4,202,094 12.98 13F 6/30/23
Morgan Stanley & Co. LLC 8.40 3,704,491 11.45 13F 6/30/23
Adage Capital Partners GP LLC 2.36 1,042,531 3.22 13F 6/30/23
OrbiMed Advisors LLC 2.09 921,940 2.85 13F 6/30/23
Rock Springs Capital Management LP 1.50 663,317 2.05 13F 6/30/23
OrbiMed Advisors Private Equity 1.11 489,106 1.51 Funds 8/31/23
Millennium Management LLC 1.06 469,002 1.45 13F 6/30/23
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.